CSL officially opened a new state-of-the-art research and development (R&D) center in Waltham, Massachusetts. The custom-built facility is approximately 140,000 square feet with 54,000 square feet of lab space, including the first biosafety level 3 laboratory (BSL-3) in Waltham. The site will serve as CSL's central hub for current and future vaccine design.
"CSL's growing R&D presence in Waltham is the latest example of our investment in our future – which includes advancing our growing capabilities in disruptive technologies like next-generation mRNA," said Jon Edelman, Senior Vice President of the CSL Vaccines Innovation Unit. "At this site, we aim to develop the vaccines that will help protect the public in the decades ahead and facilitate collaboration with local partners to drive our next wave of innovation."
CSL's global Research and Development organization has more than 2,000 employees in ten countries around the world, contributing to a robust and promising pipeline of novel therapeutic candidates. In addition to Waltham, Massachusetts, the company has an R&D presence in King of Prussia, Pennsylvania; Pasadena, California; Melbourne, Australia; Bern, Switzerland; Amsterdam, Netherlands; and Marburg, Germany – helping to create an integrated global organization that can conveniently collaborate with institutions everywhere and offer access to professional development opportunities and enhancing external innovation.
"The Waltham site's location and our investment in this world-class facility will provide our talented people with the ideal environment to deliver the breakthroughs that CSL aims to achieve," said Ethan Settembre, Ph.D., Vice President, Research, CSL Vaccines Innovation Unit and site head for this facility. "We are also excited that this location provides an opportunity for our scientists to collaborate closely with industry and academic partners, allowing greater access to ongoing innovation and talent."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!